{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:31:32Z","timestamp":1787772692579,"version":"build-2784847793"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Treatment of vitiligo is still a challenge in dermatology. Literature is sparse on the definitive clinical role of basic fibroblast growth factor (bFGF) in vitiligo patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>We decided to generate a consensus in an attempt to answer some critical questions related to the management of vitiligo and the role of bFGF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A Delphi method among 21 experts across India was conducted. A consensus (agreement was 75% or greater) was taken on 27 statements on the prevalence, epidemiology, and treatment of vitiligo and the role of bFGF in the management of vitiligo. The consensus process was completed after two rounds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Topical corticosteroid therapy is the first-line therapy for vitiligo; however, its adverse effects are widely known, especially in sensitive areas. Topical calcineurin inhibitors are preferred in stable vitiligo of the face, neck, genitals, or intertriginous regions as an alternative to topical corticosteroids. Topical bFGF is a relatively newer therapy with a promising role in stable vitiligo. bFGF is safe and effective in inducing repigmentation of vitiligo lesions. Combination therapy of bFGF with other topical therapies, phototherapy, and surgical procedures can be beneficial in patients of vitiligo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This consensus would complement the currently available literature on bFGF and help the practitioner to recognize the unmet need in the treatment of vitiligo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_461_23","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:15:18Z","timestamp":1724951718000},"page":"587","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Development of Consensus Recommendations on the Management of Vitiligo and the Role of Decapeptide in Vitiligo by the Delphi Method"],"prefix":"10.4103","volume":"68","author":[{"given":"Davinder","family":"Parsad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Kandhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachita","family":"Dhurat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Majid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikishan Kumar","family":"Yadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdish","family":"Sakhiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital","family":"Poojary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jagadish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin D.","family":"Banotkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. M.","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Jamadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Tank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Dhabhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premanshu","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshi","family":"Pandita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-26-20240829","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: A Review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"R2-26-20240829","doi-asserted-by":"crossref","first-page":"249","DOI":"10.18231\/j.ijced.2020.050","article-title":"Basic Fibroblast Growth Factor (bFGF) related decapeptide 0.1% Solution, with Tacrolimus 0.1% ointment combination therapy compared with Tacrolimus 0.1% ointment monotherapy in the treatment of stable vitiligo: A Phase IV, randomized 12 months Study","volume":"6","author":"Parsad","year":"2020","journal-title":"IP Indian J Clin Exp Dermatol"},{"key":"R3-26-20240829","first-page":"S3","article-title":"A Double Blind Randomized Phase IV Clinical Trial of basic Fibroblast Growth Factor Related Deca-peptide in Vitiligo","volume":"3","author":"Ramaiah","year":"2015","journal-title":"Pigmentary Disorders S"},{"key":"R5-26-20240829","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0378-6323.32708","article-title":"Vitiligo: Compendium of clinico-epidemiological features","volume":"73","author":"Sehgal","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R6-26-20240829","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0190-9622(96)90718-5","article-title":"Segmental vitiligo: Clinical findings in 208 patients","volume":"35","author":"Hann","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R7-26-20240829","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/gepi.1370020107","article-title":"Studies on vitiligo. I. Epidemiological profile in Calcutta, India","volume":"2","author":"Das","year":"1985","journal-title":"Genet Epidemiol"},{"key":"R8-26-20240829","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res"},{"key":"R9-26-20240829","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/pcmr.12974","article-title":"Vitiligo: Translational research and effective therapeutic strategies","volume":"34","author":"Thakur","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"R10-26-20240829","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"R11-26-20240829","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archderm.1993.01680290066010","article-title":"Pattern of familial aggregation of vitiligo","volume":"129","author":"Majumder","year":"1993","journal-title":"Arch Dermatol"},{"key":"R12-26-20240829","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/gepi.1370020303","article-title":"Studies on vitiligo. II. Familial aggregation and genetics","volume":"2","author":"Das","year":"1985","journal-title":"Genet Epidemiol"},{"key":"R13-26-20240829","first-page":"981","article-title":"Genetic epidemiology of vitiligo: Multilocus recessivity cross-validated","volume":"55","author":"Nath","year":"1994","journal-title":"Am J Hum Genet"},{"key":"R14-26-20240829","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1468-3083.2006.01899.x","article-title":"Association of vitiligo with HLA-A2: A meta-analysis","volume":"21","author":"Liu","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R15-26-20240829","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","article-title":"Genetics of Vitiligo","volume":"35","author":"Spritz","year":"2017","journal-title":"Dermatol Clin"},{"key":"R16-26-20240829","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fendo.2018.00803","article-title":"The Prevalence of Thyroid Disorders in Patients with Vitiligo: A Systematic Review and Meta-Analysis","volume":"9","author":"Yuan","year":"2018","journal-title":"Front Endocrinol (Lausanne"},{"key":"R17-26-20240829","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13223-021-00597-4","article-title":"Atopic dermatitis and risk of autoimmune diseases: A systematic review and meta-analysis","volume":"17","author":"Lu","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R18-26-20240829","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000247164","article-title":"Vitiligo and other diseases: Coexistence or true association? Hamburg study on 321 patients","volume":"188","author":"Schallreuter","year":"1994","journal-title":"Dermatology"},{"key":"R19-26-20240829","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/archderm.144.3.310","article-title":"A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases","volume":"144","author":"Birlea","year":"2008","journal-title":"Arch Dermatol"},{"key":"R20-26-20240829","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: A comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up","volume":"65","author":"Alikhan","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R21-26-20240829","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"R22-26-20240829","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1346-8138.2012.01583.x","article-title":"Piebaldism","volume":"40","author":"Oiso","year":"2013","journal-title":"J Dermatol"},{"key":"R23-26-20240829","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1468-3083.2007.02275.x","article-title":"Preliminary evaluation of vitiligo using in vivo reflectance confocal microscopy","volume":"21","author":"Ardigo","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R24-26-20240829","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2133.2008.08881.x","article-title":"Guideline for the diagnosis and management of vitiligo","volume":"159","author":"Gawkrodger","year":"2008","journal-title":"Br J Dermatol"},{"key":"R25-26-20240829","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjd.20596","article-title":"British Association of Dermatologists guidelines for the management of people with vitiligo 2021","volume":"186","author":"Eleftheriadou","year":"2022","journal-title":"Br J Dermatol"},{"key":"R26-26-20240829","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archderm.134.12.1532","article-title":"Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature","volume":"134","author":"Njoo","year":"1998","journal-title":"Arch Dermatol"},{"key":"R27-26-20240829","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: The European Dermatology Forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"key":"R28-26-20240829","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/abd1806-4841.20142717","article-title":"Vitiligo-Part 2-classification, histopathology and treatment","volume":"89","author":"Faria","year":"2014","journal-title":"An Bras Dermatol"},{"key":"R29-26-20240829","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Vitiligo Working Group Current and emerging treatments for vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R30-26-20240829","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: A systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R31-26-20240829","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/dth.12295","article-title":"Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: A meta-analysis","volume":"29","author":"Dang","year":"2016","journal-title":"Dermatol Ther"},{"key":"R32-26-20240829","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/jdv.12726","article-title":"Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: A 24-week prospective right-left comparative clinical trial","volume":"29","author":"Khullar","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R33-26-20240829","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1046\/j.1365-4362.1999.00623.x","article-title":"The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients","volume":"38","author":"Kim","year":"1999","journal-title":"Int J Dermatol"},{"key":"R34-26-20240829","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-4362.1993.tb02754.x","article-title":"Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease","volume":"32","author":"Pasricha","year":"1993","journal-title":"Int J Dermatol"},{"key":"R35-26-20240829","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2310\/7750.2013.12053","article-title":"Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo","volume":"17","author":"Kanwar","year":"2013","journal-title":"J Cutan Med Surg"},{"key":"R36-26-20240829","first-page":"41","article-title":"Comparative study of efficacy and safety of topical active fragment of basic fibroblast growth factor (B FGF) 0.1% solution V\/S betamethasone valerate 0.1% ointment in the treatment of vitiligo patients","volume":"14","author":"Subhashini","year":"2015","journal-title":"J Dent Med Sci"},{"key":"R37-26-20240829","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3892\/etm.2021.10229","article-title":"Updates and new medical treatments for vitiligo (Review)","volume":"22","author":"Kubelis-L\u00f3pez","year":"2021","journal-title":"Exp Ther Med"},{"key":"R38-26-20240829","doi-asserted-by":"crossref","first-page":"e13109","DOI":"10.1111\/dth.13109","article-title":"Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus Tacrolimus 0.1% ointment versus Tacrolimus 0.1% ointment in the treatment of stable vitiligo","volume":"32","author":"Shah","year":"2019","journal-title":"Dermatol Ther"},{"key":"R39-26-20240829","first-page":"112","article-title":"A Double Blind Randomized Clinical Trial on Basic Fibroblast Growth Factor Related Deca-Peptide to Reduce Wrinkles on Skin and to Treat Non Sun Exposed Vitiligo Macules","volume":"3","author":"Abburi","year":"2017","journal-title":"Cosmetol Oro Facial Surg"},{"key":"R40-26-20240829","doi-asserted-by":"crossref","first-page":"e13368","DOI":"10.1111\/dth.13368","article-title":"Studying the effect of adding growth factors to the autologous melanocyte keratinocyte suspension in segmental vitiligo","volume":"33","author":"Esmat","year":"2020","journal-title":"Dermatol Ther"},{"key":"R41-26-20240829","first-page":"41","article-title":"Drug UNIM-005 (herbal compound drug) and bFGF (basic fibroblast growth factor) in the treatment of stable vitiligo lesions","volume":"1","author":"Waheed","year":"2005","journal-title":"Hippocrat J Unani Med"},{"key":"R42-26-20240829","first-page":"1309","article-title":"Therapeutic management of vitiligo","volume":"16","author":"Bleuel","year":"2018","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_461_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:09:18Z","timestamp":1787771358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_461_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_461_23","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}